Biomarkers for Mood Disorders reviews candidate markers—omics, inflammatory signatures, neuroendocrine measures, sleep/circadian metrics, and imaging—that may predict treatment response or relapse in depression and bipolar spectrum conditions. This page converts complex literature into clinic-ready concepts: how to judge assay quality, when a marker might change your next step, and how to fold results into shared decisions. If you’re comparing an mood disorders conference, you’ll find pragmatic frameworks for linking markers to hypotheses (e.g., inflammation-biased depression), selecting therapies, and measuring outcomes that matter to patients.

Adoption must be careful and equitable. We emphasize transparent thresholds, replication, and cost–benefit thinking; no test should widen disparities or promise certainty it cannot deliver. Sleep and circadian measures are often actionable first steps; task/rest neuroimaging can stratify research cohorts even when not yet standard in clinic. We also show how patient-reported outcomes, digital activity, and cognition bridge lab markers to daily function. For medication-focused translation, see Precision Psychopharmacology, which aligns dosing choices with biology, tolerability, and goals.